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Editorial 
Hepatitis B Infection and Liver Transplantation: The Art of 
the Possible 
If a lot of cures are suggested for a disease, it means that the disease is incurable. 
Anton Chekhov 
Liver transplantation seems to be a lightning rod for 
many of the criticisms directed against high-technology 
tertiary care medicine. After the National Institutes of 
Health consensus conference declared in 1983 that 
“liver transplantation is a therapeutic modality for 
end-stage liver disease that deserves broader applica- 
tion” (l), there followed a period of remarkable growth. 
The number of liver transplants performed in the 
United States increased from 15 in 1985 to 2,656 by 
1990, and the number of liver transplant centers grew 
during the same period from 1 to 85 (2). The spirit of 
optimism that fostered this expansion has given way to 
a spirit of retrenchment, spurred in part by the general 
reassessment of public-health policy in the United 
States. Liver transplantation is vely expensive and very 
labor-intensive and benefits relatively few patients. 
Many of these criticisms could be rebutted by convincing 
evidence that liver transplantation is an efficacious 
remedy for otherwise untreatable disease. Unfortu- 
nately, liver transplantation does not lend itself to 
randomized clinical studies of its efficacy. Physicians 
involved in liver transplant programs usually lack 
“equipoise” with regard to liver transplantation for 
their patients (3). In other words, because liver trans- 
plant physicians and surgeons are convinced that liver 
transplantation is the appropriate treatment for selected 
patients, they cannot in good conscience randomly 
allocate some of the same patients to a nontransplant 
arm of a clinical study. Nonetheless, it is incontro- 
vertible that liver transplantation has been a lifesaving 
procedure for many patients who otherwise would have 
died. For example, among a cohort of alcoholic patients 
with end-stage liver disease who underwent transplan- 
tation evaluation, survival in the transplant recipients 
was significantly greater than that among patients not 
selected for transplantation 14). Indeed, it is this 
HEPATOLCGY 1994;19:245-247 
Address reprint requests to: Michael R. Lucey. M.D.. F.R.C.P.I., Associate 
Professor of Medicine, Medical Director, Liver Transplant Program. University 
of Michigan Medical Center, 3912 Taubman Center, Box 0362, 1500 East 
Medical Center Drive, Ann Arbor, MI 48109. 
Copyright 0 1994 by the American Association for the Study of Liver 
Diseases. 
0270-9139/94 $1.00 + .10 31/1/51426 
perception of success that has fed the demand for liver 
transplantation. 
A major limitation of the more widespread provision of 
liver transplantation is the lack of suitable donor organs. 
The demand for transplant livers has grown to outstrip 
the supply. As a result, the number of patients waiting 
for a liver transplant and the mean number of days each 
candidate waits continue to increase; inevitably the 
number of patients dying for want of a liver transplant 
has grown also ( 5 ) .  This crisis is forcing reconsideration 
of the goals of liver transplantation. Each time a donor 
liver is allocated to one particular recipient, other 
potential recipients are denied use of the same allograft. 
Many factors, includlng the patient’s underlying diag- 
nosis and severity of clinical decompensation, as indi- 
cated by the presence of kidney failure or the need for 
intensive care management before transplant, interact 
to affect the prognosis for successful engraftment and 
recovery (6). Given that we are able to allocate scarce 
donor organs to a few patients with end-stage liver 
disease only, what influence should the likelihood 
of a successful outcome have on the judgment of a 
potential candidate’s suitability for transplant? The 
present United Network of Organ Sharing system is 
constructed to give priority to patients with the most 
immediate risk of dying. Approximately half of all 
recipients were stable (status 1 and 2) and half were 
more urgently ill (status 3 and 4) a t  time of transplant 
in 1992 (7). The philosophic basis of the system is to 
treat the most severely ill patients first, even though 
these patients are at greatest risk of postoperative 
mortality. 
Chronic HBV infection presents a different aspect of 
the same dilemma. HBV-infected patients with end- 
stage liver disease are often good surgical risks. Unfor- 
tunately, posttransplant infection of the allograft by 
HBV is very common, and the reported overall survival 
of HBV-infected patients who undergo transplantation 
is reduced. For example, Starzl et al. reported that the 
24-mo survival after liver transplantation was 50% in 51 
adults with HBV infection, compared with 76% in 744 
adults given transplants for nonmalignant disease (8). 
Recurrent HBV infection in the allograft may be 
associated with an aggressive syndrome with the pro- 
duction of massive amounts of HBV proteins, which has 
been termed “ fibrosing cholestatic hepatitis” (9). None- 
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theless, the picture is not always gloomy. Some HBV- 
infected recipients, particularly patients coinfected with 
HDV, may tolerate HBV without obvious harmful 
effects and survive for many years after transplantation 
(10). 
Because liver transplantation rarely cures chronic 
HBV infection, it has been questioned whether patients 
with chronic HBV infection should be considered appro- 
priate liver transplant candidates. It is against this 
background that Marcellin’s study in this issue of 
HEPATOLOGY provides important data (11). They studied 
the use of interferon-a (IFN-a) in a group of patients 
with chronic hepatitis B infection and end-stage liver 
disease awaiting liver transplantation. The rationale for 
their study was sound. Previous studies had suggested 
that the risk for graft infection appeared to be greatest 
in patients with actively replicating HBV (12). 
Treatment of HBV infection with IFN-a can convert 
serum markers of viral replication (HBeAg, HBV DNA) 
to markers of less or no replication (HBe antibody 
[anti-HBel, absence of HBV DNA on standard hybrid- 
ization techniques). This occurs in 40% to 50% of cases, 
whereas clearance of HBsAg occurs in a smaller per- 
centage (13). Therefore, Marcellin et al. attempted to 
reduce the risk of infection of the graft by controlling 
HBV infection with administration of IFN-a in the 
pretransplant phase. Although they did not achieve all 
their goals, their results are important. Two of 22 
patients had clinical serological and biochemical im- 
provement, including loss of serum HBV DNA, allowing 
them to be taken off the waiting list. On the other hand, 
one patient deteriorated while on interferon, and spon- 
taneous bacterial peritonitis developed. This patient 
subsequently improved with loss of HBV DNA from 
serum, appearance of anti-HBe and normal serum 
aminotransferase levels and was alive after 40 mo 
without a transplant. IFN therapy in such a decompen- 
sated group of patients is hazardous, and eight of 22 
patients required dosage reduction. 
Eighteen IFN-treated patients underwent transplan- 
tation, and their results were compared with those in 26 
historical controls. All patients received long-term 
immunoprophylaxis after transplantation. Previous 
studies by this group suggest that passive immunization 
with high doses of hyperimmune B Ig (HBIg) reduces the 
frequency of infection of the allograft with HBV (14). 
Marcellin and coworkers found that although IFN 
appeared to affect the viral load, it was ineffective in 
completely eradicating the virus before transplantation, 
and infection rates in the allograft were similar in 
IFN-treated and untreated patients (11). The antiviral 
effect was demonstrated by the disappearance of HBV 
DNA measured with dot-blot hybridization in seven of 
eight patients. However, in four of five patients who 
became HBV DNA negative during IFN therapy before 
transplantation HBV infection subsequently developed 
in their allografts. This observation was accounted for 
by means of analysis of stored pretransplant sera which 
indicated that persistence of the HBV genome, detected 
on PCR amplification rather than by means of standard 
hybridization methods, was highly associated with in- 
fection of the allograft. Thus it would appear that 
nothing short of complete eradication of the virus will 
protect against allograft infection. 
What lessons are to be drawn from these studies, 
particularly in the light of the constraints on liver 
transplantation described earlier? First, we must define 
the goals of therapy. Until better therapies become 
available, curing the patient of HBV before transplan- 
tation by means of IFN is an unattainable goal (11, 15). 
Marcellin’s observation that 2 of 22 patients improved 
sufficiently to forestall liver transplantation is inter- 
esting and worthy of further study. Hoofnagle et al. 
noted similarly that IFN treatment of patients with 
cirrhosis due to HBV infection, while carrying the risk of 
precipitating further deterioration, was associated with 
dramatic clinical improvement in some cases (16). It is 
appropriate to treat selected HBV-infected patients to 
this end alone. We need more studies to identify those 
patients most likely to respond in this way. It should be 
noted that pretransplant IFN should be administered in 
low doses and that a substantial portion of patients may 
require dose reduction. Second, this French group 
pioneered the use of posttransplant immunoprophylaxis 
with long-term high-dose p a r e n t e d  HBIg, and its role 
must be studied further. Even in France, as Marcellin’s 
study shows, HBIg does not prevent recurrence of HBV 
in the graft. The PCR data presented here suggest that 
viremia at  the time of transplant is the most important 
factor in determining posttransplant infection of the 
allograft. Marcellin’s study included HBsAg-positive, 
anti-HBepositive, HBV DNA-negative patients. The 
risk that these patients would infect the allograft is 
presumably less than that in patients with a high degree 
of viral replication. The role of HBIg should ideally be 
tested in a prospective randomized trial that takes the 
HBV replicative status of the participants into account. 
This has not been possible in the United States because 
of difficulty in procuring a supply of HBIg, especially 
because the Food and Drug Administration has not 
approved an HBIg formulation suitable for intravenous 
use. Third, Marcellin’s study shows that it is possible to 
manipulate HBV infection in patients awaiting liver 
transplantation, even if the ultimate goal of curing HBV 
has proved elusive. Research should be directed at 
examining the reasons why IFN is not more successful 
in eradicating HBV and identifying the factors that 
determine whether an allograft will become infected by 
HBV. These might include persistence of virus in 
extrahepatic sites (171, viral genetic mutation (18) or 
viral characteristics that reduce the efficacy of IFN (19). 
Similarly, study of more effective therapeutic agents, 
combinations of agents or use of baboon xenografts (20) 
should continue. 
Finally, in my view, liver transplantation for patients 
with HBV infection should not be abandoned simply 
because it is not curative, although some acknowl- 
edgment of the donor shortage is appropriate. At the 
University of Michigan, we have adopted a policy of 
offering transplantation only to HBV-infected patients 
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who are suitable candidates in all other respects. We will 8. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. 
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Alexander GJM, waiamS R. Hepatic histologid findings after 
transplantation for chronic hepatitis B virus infection, including a 
not perform a second if the primary ‘lograft 9, Davies SE, portm&, BC, O’Grady JG. PM, Chaggar K,  fads because of recurrent HBV infection. A similar policy 
of one donor organ per HBV-infected candidate has also 
been followed -in Toronto, albeit with the further 
restriction that only patients who test negative for HBV 
DNA in Serum by Of standard hybridization 
methods will be considered for transplantation (Levy G ,  
unique pattern of fibrosing cholestatic hepatitis. HEPATOLOGY 
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Waggoner JG, Merion RM, et al. Recurrence of hepatitis B and 
delta hepatitis after orthotopic liver transplantation. Gut 1992; 
Personal communication, 1993). Until a consensus 33:1390-1396. 
about the place of liver transplantation in management 
of HBV infection has been reached, it is reasonable to 
continue to include liver transplantation in the battery 
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M, David MF, et al. Pretransplantation interferon treatment and 
recurrence of HBV infection after liver transplantation for 
hepatitis B related end stage liver disease. HEPATOLOGY 1994;19: 
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